JP2014510055A - ホスホジエステラーゼ１０（ｐｄｅ１０ａ）阻害剤としての置換６，７−ジアルコキシ−３−イソキノリノール誘導体 - Google Patents
ホスホジエステラーゼ１０（ｐｄｅ１０ａ）阻害剤としての置換６，７−ジアルコキシ−３−イソキノリノール誘導体 Download PDFInfo
- Publication number
- JP2014510055A JP2014510055A JP2013554657A JP2013554657A JP2014510055A JP 2014510055 A JP2014510055 A JP 2014510055A JP 2013554657 A JP2013554657 A JP 2013554657A JP 2013554657 A JP2013554657 A JP 2013554657A JP 2014510055 A JP2014510055 A JP 2014510055A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- disorder
- dimethoxy
- dihydrochloride
- isoquinolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title abstract description 15
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title abstract description 15
- 239000003112 inhibitor Substances 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 124
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 117
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 32
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 208000008589 Obesity Diseases 0.000 claims abstract description 23
- 235000020824 obesity Nutrition 0.000 claims abstract description 23
- 208000002193 Pain Diseases 0.000 claims abstract description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 11
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 9
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 9
- 208000002705 Glucose Intolerance Diseases 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 176
- 208000035475 disorder Diseases 0.000 claims description 93
- -1 azido, hydroxyl Chemical group 0.000 claims description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 62
- 201000000980 schizophrenia Diseases 0.000 claims description 55
- 206010012289 Dementia Diseases 0.000 claims description 39
- 241000124008 Mammalia Species 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 34
- 208000018737 Parkinson disease Diseases 0.000 claims description 33
- 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 claims description 31
- 208000023105 Huntington disease Diseases 0.000 claims description 31
- 230000004770 neurodegeneration Effects 0.000 claims description 31
- 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 claims description 29
- 208000019901 Anxiety disease Diseases 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 25
- 230000036651 mood Effects 0.000 claims description 24
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 208000020925 Bipolar disease Diseases 0.000 claims description 20
- 208000019022 Mood disease Diseases 0.000 claims description 20
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 20
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims description 20
- 208000024827 Alzheimer disease Diseases 0.000 claims description 19
- 206010013663 drug dependence Diseases 0.000 claims description 19
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 18
- 208000020401 Depressive disease Diseases 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 18
- 208000011117 substance-related disease Diseases 0.000 claims description 18
- 208000024891 symptom Diseases 0.000 claims description 18
- 208000006011 Stroke Diseases 0.000 claims description 16
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 16
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- 208000016285 Movement disease Diseases 0.000 claims description 15
- 208000024714 major depressive disease Diseases 0.000 claims description 15
- 208000024254 Delusional disease Diseases 0.000 claims description 14
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 14
- 206010061216 Infarction Diseases 0.000 claims description 13
- 230000019771 cognition Effects 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 230000007574 infarction Effects 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000017442 Retinal disease Diseases 0.000 claims description 11
- 206010026749 Mania Diseases 0.000 claims description 10
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000004104 aryloxy group Chemical group 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 208000019906 panic disease Diseases 0.000 claims description 10
- 230000002207 retinal effect Effects 0.000 claims description 10
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 9
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 9
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 8
- RHWRUUIHGOVMGV-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(propylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCCC)=C(O)N=C(CCC)C2=C1 RHWRUUIHGOVMGV-UHFFFAOYSA-N 0.000 claims description 8
- 201000007737 Retinal degeneration Diseases 0.000 claims description 8
- 229940025084 amphetamine Drugs 0.000 claims description 8
- 229960003920 cocaine Drugs 0.000 claims description 8
- 230000007812 deficiency Effects 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 208000022821 personality disease Diseases 0.000 claims description 8
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 7
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- 208000002780 macular degeneration Diseases 0.000 claims description 7
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 7
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 208000001344 Macular Edema Diseases 0.000 claims description 6
- 206010038910 Retinitis Diseases 0.000 claims description 6
- 125000005001 aminoaryl group Chemical group 0.000 claims description 6
- 230000003001 depressive effect Effects 0.000 claims description 6
- 210000000981 epithelium Anatomy 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- DVDXVRDJQQVUQP-UHFFFAOYSA-N 4-(isoquinolin-6-ylmethyl)-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C1=NC=CC2=CC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=C21 DVDXVRDJQQVUQP-UHFFFAOYSA-N 0.000 claims description 5
- YJEOYSAOUKBEIO-UHFFFAOYSA-N 4-[(7-ethoxyquinolin-3-yl)methyl]-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC=C(C=C4N=C3)OCC)=C(O)N=C(C)C2=C1 YJEOYSAOUKBEIO-UHFFFAOYSA-N 0.000 claims description 5
- FGFCTKRLUAPAEZ-UHFFFAOYSA-N 4-[[2-(benzylamino)-6-methoxyquinolin-3-yl]methyl]-1-ethyl-6,7-dimethoxy-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCC1=CC=CC=C1 FGFCTKRLUAPAEZ-UHFFFAOYSA-N 0.000 claims description 5
- JHIDGKNWYWURNG-UHFFFAOYSA-N 4-[[2-(ethylamino)-6-methylquinolin-3-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(C)=CC=C2N=C1NCC JHIDGKNWYWURNG-UHFFFAOYSA-N 0.000 claims description 5
- LZABEZCAFNVNPM-UHFFFAOYSA-N 4-[[6-ethoxy-2-(ethylamino)quinolin-3-yl]methyl]-1-ethyl-6,7-dimethoxy-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OCC)=CC=C4N=C3NCC)=C(O)N=C(CC)C2=C1 LZABEZCAFNVNPM-UHFFFAOYSA-N 0.000 claims description 5
- BDZZBGQSXGATGK-UHFFFAOYSA-N 4-[[6-ethoxy-2-(ethylamino)quinolin-3-yl]methyl]-6,7-dimethoxy-1-propan-2-yl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OCC)=CC=C4N=C3NCC)=C(O)N=C(C(C)C)C2=C1 BDZZBGQSXGATGK-UHFFFAOYSA-N 0.000 claims description 5
- OBGRQVSZJGXHIY-UHFFFAOYSA-N 4-benzyl-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC1=CC=CC=C1 OBGRQVSZJGXHIY-UHFFFAOYSA-N 0.000 claims description 5
- HYUHVXKLZJJXCZ-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-(quinolin-3-ylmethyl)-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C1=CC=CC2=CC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CN=C21 HYUHVXKLZJJXCZ-UHFFFAOYSA-N 0.000 claims description 5
- RWVQJRXECYTDTP-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-(quinolin-4-ylmethyl)-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C1=CC=C2C(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=NC2=C1 RWVQJRXECYTDTP-UHFFFAOYSA-N 0.000 claims description 5
- DNXMINHITKWZHM-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[[6-methyl-2-(methylamino)quinolin-3-yl]methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(C)=CC=C4N=C3NC)=C(O)N=C(C)C2=C1 DNXMINHITKWZHM-UHFFFAOYSA-N 0.000 claims description 5
- KUNTZLSIGITAIM-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(methylamino)quinolin-3-yl]methyl]-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NC)=C(O)N=C(C)C2=C1 KUNTZLSIGITAIM-UHFFFAOYSA-N 0.000 claims description 5
- 208000031091 Amnestic disease Diseases 0.000 claims description 5
- 241000218236 Cannabis Species 0.000 claims description 5
- 208000002691 Choroiditis Diseases 0.000 claims description 5
- 206010012218 Delirium Diseases 0.000 claims description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 5
- 208000013016 Hypoglycemia Diseases 0.000 claims description 5
- 206010021030 Hypomania Diseases 0.000 claims description 5
- 208000020358 Learning disease Diseases 0.000 claims description 5
- 206010025415 Macular oedema Diseases 0.000 claims description 5
- 208000036626 Mental retardation Diseases 0.000 claims description 5
- 208000003971 Posterior uveitis Diseases 0.000 claims description 5
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims description 5
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 5
- 206010038848 Retinal detachment Diseases 0.000 claims description 5
- 208000016624 Retinal neoplasm Diseases 0.000 claims description 5
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 5
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 208000026345 acute stress disease Diseases 0.000 claims description 5
- 230000007000 age related cognitive decline Effects 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 5
- 206010013932 dyslexia Diseases 0.000 claims description 5
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 5
- 239000000380 hallucinogen Substances 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 5
- 238000007917 intracranial administration Methods 0.000 claims description 5
- 201000003723 learning disability Diseases 0.000 claims description 5
- 201000010230 macular retinal edema Diseases 0.000 claims description 5
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims description 5
- 229950010883 phencyclidine Drugs 0.000 claims description 5
- 230000004264 retinal detachment Effects 0.000 claims description 5
- 239000000790 retinal pigment Substances 0.000 claims description 5
- 230000000698 schizophrenic effect Effects 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- MGRGSGSEPNEPJE-UHFFFAOYSA-N 1-ethyl-4-[[2-(ethylamino)-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCC)=C(O)N=C(CC)C2=C1 MGRGSGSEPNEPJE-UHFFFAOYSA-N 0.000 claims description 4
- BGTMPYLBFUAQHC-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-(naphthalen-2-ylmethyl)-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC=C(C=CC=C2)C2=C1 BGTMPYLBFUAQHC-UHFFFAOYSA-N 0.000 claims description 4
- ADIJDXVEENNLQW-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[(3-phenylphenyl)methyl]-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC(C=1)=CC=CC=1C1=CC=CC=C1 ADIJDXVEENNLQW-UHFFFAOYSA-N 0.000 claims description 4
- OONPRRFULQGCFN-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[3-(4-methoxyphenyl)phenyl]methyl]-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC(C=1)=CC=CC=1C1=CC=C(OC)C=C1 OONPRRFULQGCFN-UHFFFAOYSA-N 0.000 claims description 4
- UGQXZYFFZMDDNW-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[6-methoxy-2-(2,2,2-trifluoroethylamino)quinolin-3-yl]methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCC(F)(F)F UGQXZYFFZMDDNW-UHFFFAOYSA-N 0.000 claims description 4
- HKWJSECIAGWHAV-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[6-methoxy-2-(methylamino)quinolin-3-yl]methyl]-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NC HKWJSECIAGWHAV-UHFFFAOYSA-N 0.000 claims description 4
- FQRJDTOPZUNTSF-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[6-methoxy-2-(propan-2-ylamino)quinolin-3-yl]methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NC(C)C FQRJDTOPZUNTSF-UHFFFAOYSA-N 0.000 claims description 4
- FBANUZRHSYFYSB-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[6-methoxy-2-(propylamino)quinolin-3-yl]methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCCC)=C(O)N=C(CC)C2=C1 FBANUZRHSYFYSB-UHFFFAOYSA-N 0.000 claims description 4
- HFVNDVLCVJBYIK-UHFFFAOYSA-N 3,6,7-trimethoxy-1-methyl-4-(naphthalen-2-ylmethyl)isoquinoline;hydrochloride Chemical compound Cl.C1=CC=CC2=CC(CC=3C(OC)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=C21 HFVNDVLCVJBYIK-UHFFFAOYSA-N 0.000 claims description 4
- BSLRKZKLHQQATI-UHFFFAOYSA-N 4-(dibenzofuran-2-ylmethyl)-1-ethyl-6,7-dimethoxy-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC=C(OC=2C3=CC=CC=2)C3=C1 BSLRKZKLHQQATI-UHFFFAOYSA-N 0.000 claims description 4
- FNMCICHSSNPOEH-UHFFFAOYSA-N 4-(dibenzofuran-2-ylmethyl)-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC=C(OC=2C3=CC=CC=2)C3=C1 FNMCICHSSNPOEH-UHFFFAOYSA-N 0.000 claims description 4
- FMSANJIVZDRHEG-UHFFFAOYSA-N 4-(isoquinolin-5-ylmethyl)-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one Chemical compound N1=CC=C2C(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=CC2=C1 FMSANJIVZDRHEG-UHFFFAOYSA-N 0.000 claims description 4
- SZVUGARWWCBPPS-UHFFFAOYSA-N 4-[(3,4-dimethoxyphenyl)methyl]-3,6,7-trimethoxy-1-methylisoquinoline;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=C(OC)N=C(C)C2=CC(OC)=C(OC)C=C12 SZVUGARWWCBPPS-UHFFFAOYSA-N 0.000 claims description 4
- ZMXLGFVWEKNIFA-UHFFFAOYSA-N 4-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=C(O)N=C(C)C2=CC(OC)=C(OC)C=C12 ZMXLGFVWEKNIFA-UHFFFAOYSA-N 0.000 claims description 4
- SEJVWBQHLJOKGQ-UHFFFAOYSA-N 4-[(5-ethoxyquinolin-3-yl)methyl]-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CN=C4C=CC=C(C4=C3)OCC)=C(O)N=C(C)C2=C1 SEJVWBQHLJOKGQ-UHFFFAOYSA-N 0.000 claims description 4
- BNKALYVAAPXYND-UHFFFAOYSA-N 4-[[2-(ethylamino)-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCC BNKALYVAAPXYND-UHFFFAOYSA-N 0.000 claims description 4
- YDOCMNYSXCPSGC-UHFFFAOYSA-N 4-[[6-ethoxy-2-(ethylamino)quinolin-3-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OCC)=CC=C2N=C1NCC YDOCMNYSXCPSGC-UHFFFAOYSA-N 0.000 claims description 4
- VBLBHZVNNFZXJC-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-(naphthalen-2-ylmethyl)-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C1=CC=CC2=CC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=C21 VBLBHZVNNFZXJC-UHFFFAOYSA-N 0.000 claims description 4
- JCQYYVCQQQMDBZ-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-(pyridin-4-ylmethyl)-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC1=CC=NC=C1 JCQYYVCQQQMDBZ-UHFFFAOYSA-N 0.000 claims description 4
- PKHZFDNFJKIBGX-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-(quinolin-6-ylmethyl)-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.N1=CC=CC2=CC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=C21 PKHZFDNFJKIBGX-UHFFFAOYSA-N 0.000 claims description 4
- PQSLORMBUZTAIR-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[(3-phenoxyphenyl)methyl]-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC(C=1)=CC=CC=1OC1=CC=CC=C1 PQSLORMBUZTAIR-UHFFFAOYSA-N 0.000 claims description 4
- FIEYUBKHKCVORP-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[(4-phenoxyphenyl)methyl]-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC(C=C1)=CC=C1OC1=CC=CC=C1 FIEYUBKHKCVORP-UHFFFAOYSA-N 0.000 claims description 4
- NODLAOREKXDBOK-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[(5-phenylpyridin-3-yl)methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC(C=1)=CN=CC=1C1=CC=CC=C1 NODLAOREKXDBOK-UHFFFAOYSA-N 0.000 claims description 4
- UOAKZBHURWPBOK-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[(6-phenylpyridin-2-yl)methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC(N=1)=CC=CC=1C1=CC=CC=C1 UOAKZBHURWPBOK-UHFFFAOYSA-N 0.000 claims description 4
- DAKABUXELXLYOR-UHFFFAOYSA-N 6,7-dimethoxy-4-(naphthalen-2-ylmethyl)-1-propyl-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC=C(C=CC=C2)C2=C1 DAKABUXELXLYOR-UHFFFAOYSA-N 0.000 claims description 4
- ZHSSSQRURJOYPA-UHFFFAOYSA-N 6,7-dimethoxy-4-[(5-methoxyquinolin-3-yl)methyl]-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C1=CC=C(OC)C2=CC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CN=C21 ZHSSSQRURJOYPA-UHFFFAOYSA-N 0.000 claims description 4
- GZQFKZILSHRCLQ-UHFFFAOYSA-N 6,7-dimethoxy-4-[(7-methoxyquinolin-3-yl)methyl]-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC=C(C=C4N=C3)OC)=C(O)N=C(C)C2=C1 GZQFKZILSHRCLQ-UHFFFAOYSA-N 0.000 claims description 4
- QRBAUUCYXVMNPO-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-(4-methoxyphenyl)pyridin-2-yl]methyl]-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1C1=CC=CC(CC=2C3=CC(OC)=C(OC)C=C3C(C)=NC=2O)=N1 QRBAUUCYXVMNPO-UHFFFAOYSA-N 0.000 claims description 4
- GWENWLLTWAKHQN-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(2,2,2-trifluoroethylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCC(F)(F)F GWENWLLTWAKHQN-UHFFFAOYSA-N 0.000 claims description 4
- MHURYTZHRWHSAM-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(methylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NC MHURYTZHRWHSAM-UHFFFAOYSA-N 0.000 claims description 4
- JJHGVTORLVSJBS-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(propan-2-ylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NC(C)C JJHGVTORLVSJBS-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 208000032578 Inherited retinal disease Diseases 0.000 claims description 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims description 4
- 208000022372 Reading disease Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 208000032430 Retinal dystrophy Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 208000028810 Shared psychotic disease Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 4
- 150000001540 azides Chemical class 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical group C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 4
- 201000006321 fundus dystrophy Diseases 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 230000002503 metabolic effect Effects 0.000 claims description 4
- DOPLUZLCSSWCKY-UHFFFAOYSA-N n-[2-[[3-[(6,7-dimethoxy-3-oxo-1-propyl-2h-isoquinolin-4-yl)methyl]-6-methoxyquinolin-2-yl]amino]ethyl]acetamide;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCCNC(C)=O DOPLUZLCSSWCKY-UHFFFAOYSA-N 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 230000004258 retinal degeneration Effects 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- PLNFMLXCFNHUGV-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[(7-methoxyquinolin-3-yl)methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CN=C(C=C(OC)C=C2)C2=C1 PLNFMLXCFNHUGV-UHFFFAOYSA-N 0.000 claims description 3
- ZDCFYQHSRMELKU-UHFFFAOYSA-N 4-[[2-(dimethylamino)-6-methylquinolin-3-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(C)=CC=C2N=C1N(C)C ZDCFYQHSRMELKU-UHFFFAOYSA-N 0.000 claims description 3
- BYNAPGZGYUBTOW-UHFFFAOYSA-N 4-[[2-(ethylamino)-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-1-propan-2-yl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCC)=C(O)N=C(C(C)C)C2=C1 BYNAPGZGYUBTOW-UHFFFAOYSA-N 0.000 claims description 3
- XBCIZFMCIKUBPM-UHFFFAOYSA-N 4-[[3-(3-aminophenyl)phenyl]methyl]-1-ethyl-6,7-dimethoxy-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC(C=1)=CC=CC=1C1=CC=CC(N)=C1 XBCIZFMCIKUBPM-UHFFFAOYSA-N 0.000 claims description 3
- VDIAHDKFSPYZCR-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-(quinolin-2-ylmethyl)-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C1=CC=CC2=NC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=C21 VDIAHDKFSPYZCR-UHFFFAOYSA-N 0.000 claims description 3
- IUMGRGJQPHURSV-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[(6-pyridin-4-ylpyridin-2-yl)methyl]-2h-isoquinolin-3-one;trihydrochloride Chemical compound Cl.Cl.Cl.C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC(N=1)=CC=CC=1C1=CC=NC=C1 IUMGRGJQPHURSV-UHFFFAOYSA-N 0.000 claims description 3
- FRQGPQPHXBSQPB-UHFFFAOYSA-N 6,7-dimethoxy-4-[(7-methoxyquinolin-3-yl)methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CN=C(C=C(OC)C=C2)C2=C1 FRQGPQPHXBSQPB-UHFFFAOYSA-N 0.000 claims description 3
- AISBYBQYHDJIOJ-UHFFFAOYSA-N 6,7-dimethoxy-4-[[5-(4-methoxyphenyl)pyridin-3-yl]methyl]-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1C1=CN=CC(CC=2C3=CC(OC)=C(OC)C=C3C(C)=NC=2O)=C1 AISBYBQYHDJIOJ-UHFFFAOYSA-N 0.000 claims description 3
- ZOOFOWYODXELAA-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(2,2,2-trifluoroethylamino)quinolin-3-yl]methyl]-1-propan-2-yl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC=3C(NCC(F)(F)F)=NC4=CC=C(C=C4C=3)OC)=C(O)N=C(C(C)C)C2=C1 ZOOFOWYODXELAA-UHFFFAOYSA-N 0.000 claims description 3
- ZOTRUCVXAQRWTN-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methyl-2-(methylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(C)=CC=C2N=C1NC ZOTRUCVXAQRWTN-UHFFFAOYSA-N 0.000 claims description 3
- 208000034461 Progressive cone dystrophy Diseases 0.000 claims description 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 208000022257 bipolar II disease Diseases 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 230000007278 cognition impairment Effects 0.000 claims description 3
- 201000008615 cone dystrophy Diseases 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 210000001525 retina Anatomy 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- BTSKXFMPMDCFCA-UHFFFAOYSA-N 1-ethyl-4-[[2-(ethylamino)-7-fluoro-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=C(F)C=C4N=C3NCC)=C(O)N=C(CC)C2=C1 BTSKXFMPMDCFCA-UHFFFAOYSA-N 0.000 claims description 2
- DJJPQDXBFFRDNN-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-(quinolin-3-ylmethyl)-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CN=C(C=CC=C2)C2=C1 DJJPQDXBFFRDNN-UHFFFAOYSA-N 0.000 claims description 2
- VBYLUENSVNFKPN-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[(2-methylquinolin-6-yl)methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC=C(N=C(C)C=C2)C2=C1 VBYLUENSVNFKPN-UHFFFAOYSA-N 0.000 claims description 2
- HTODCQDAVFLCGE-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[(6-methoxyquinolin-3-yl)methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CN=C(C=CC(OC)=C2)C2=C1 HTODCQDAVFLCGE-UHFFFAOYSA-N 0.000 claims description 2
- NOIJZVSXLMQEJL-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[6-(methylamino)-[1,3]dioxolo[4,5-g]quinolin-7-yl]methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC(C(=NC1=C2)NC)=CC1=CC1=C2OCO1 NOIJZVSXLMQEJL-UHFFFAOYSA-N 0.000 claims description 2
- IEQURDALEIJEIX-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[6-methoxy-2-(2-methoxyethylamino)quinolin-3-yl]methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCCOC IEQURDALEIJEIX-UHFFFAOYSA-N 0.000 claims description 2
- OSTDSZLKWVKGAL-UHFFFAOYSA-N 4-[(2-azido-6-methoxyquinolin-3-yl)methyl]-1-ethyl-6,7-dimethoxy-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1N=[N+]=[N-] OSTDSZLKWVKGAL-UHFFFAOYSA-N 0.000 claims description 2
- LINJDHXBERWBQA-UHFFFAOYSA-N 4-[(2-butyl-6-methoxyquinolin-3-yl)methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3CCCC)=C(O)N=C(CCC)C2=C1 LINJDHXBERWBQA-UHFFFAOYSA-N 0.000 claims description 2
- XTYBJTMZTAVKPZ-UHFFFAOYSA-N 4-[(2-ethyl-6-methoxyquinolin-3-yl)methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1CC XTYBJTMZTAVKPZ-UHFFFAOYSA-N 0.000 claims description 2
- KAGDIIFYXXVWJH-UHFFFAOYSA-N 4-[2-(ethylamino)-6-methoxyquinoline-3-carbonyl]-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(C(=O)C3=CC4=CC(OC)=CC=C4N=C3NCC)=C(O)N=C(C)C2=C1 KAGDIIFYXXVWJH-UHFFFAOYSA-N 0.000 claims description 2
- YXQJQBZCXNFOKH-UHFFFAOYSA-N 4-[[2-(ethylamino)-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-1-(methoxymethyl)-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCC)=C(O)N=C(COC)C2=C1 YXQJQBZCXNFOKH-UHFFFAOYSA-N 0.000 claims description 2
- ZWRMGTDJFIHXIG-UHFFFAOYSA-N 4-[[2-(ethylamino)-7-fluoro-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=C(F)C=C2N=C1NCC ZWRMGTDJFIHXIG-UHFFFAOYSA-N 0.000 claims description 2
- SWBCIDGZDZCQKC-UHFFFAOYSA-N 4-[[6,7-dihydroxy-2-(methylamino)quinolin-3-yl]methyl]-6,7-dimethoxy-1-methyl-2H-isoquinolin-3-one dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(O)=C(O)C=C4N=C3NC)=C(O)N=C(C)C2=C1 SWBCIDGZDZCQKC-UHFFFAOYSA-N 0.000 claims description 2
- KUCSXSVAROGQCH-UHFFFAOYSA-N 4-[[6-(dimethylamino)-[1,3]dioxolo[4,5-g]quinolin-7-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC(C(=NC1=C2)N(C)C)=CC1=CC1=C2OCO1 KUCSXSVAROGQCH-UHFFFAOYSA-N 0.000 claims description 2
- VGFOROIFWFIFDX-UHFFFAOYSA-N 4-[[6-(ethylamino)-[1,3]dioxolo[4,5-g]quinolin-7-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC(C(=NC1=C2)NCC)=CC1=CC1=C2OCO1 VGFOROIFWFIFDX-UHFFFAOYSA-N 0.000 claims description 2
- YZDNDYZIYOBDLJ-UHFFFAOYSA-N 4-[[6-ethoxy-2-(ethylamino)-7-fluoroquinolin-3-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OCC)=C(F)C=C2N=C1NCC YZDNDYZIYOBDLJ-UHFFFAOYSA-N 0.000 claims description 2
- PZECIDJODGHFEA-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[[6-(methylamino)-[1,3]dioxolo[4,5-g]quinolin-7-yl]methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC=5OCOC=5C=C4N=C3NC)=C(O)N=C(C)C2=C1 PZECIDJODGHFEA-UHFFFAOYSA-N 0.000 claims description 2
- LNSIGEGUPKGHDL-UHFFFAOYSA-N 6,7-dimethoxy-1-propan-2-yl-4-(quinolin-3-ylmethyl)-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C1=CC=CC2=CC(CC3=C4C=C(C(=CC4=C(C(C)C)N=C3O)OC)OC)=CN=C21 LNSIGEGUPKGHDL-UHFFFAOYSA-N 0.000 claims description 2
- KBYPBHQYLMZWOF-UHFFFAOYSA-N 6,7-dimethoxy-1-propyl-4-(quinolin-3-ylmethyl)-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CN=C(C=CC=C2)C2=C1 KBYPBHQYLMZWOF-UHFFFAOYSA-N 0.000 claims description 2
- OEIKCOFHXZCRTE-UHFFFAOYSA-N 6,7-dimethoxy-4-[(2-methylquinolin-6-yl)methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC=C(N=C(C)C=C2)C2=C1 OEIKCOFHXZCRTE-UHFFFAOYSA-N 0.000 claims description 2
- GVNGURGDKRZERV-UHFFFAOYSA-N 6,7-dimethoxy-4-[(6-methoxyquinolin-3-yl)methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CN=C(C=CC(OC)=C2)C2=C1 GVNGURGDKRZERV-UHFFFAOYSA-N 0.000 claims description 2
- DHJAWBRYBVKAKG-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-(methylamino)-[1,3]dioxolo[4,5-g]quinolin-7-yl]methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC(C(=NC1=C2)NC)=CC1=CC1=C2OCO1 DHJAWBRYBVKAKG-UHFFFAOYSA-N 0.000 claims description 2
- MPAYZJKTQWPELV-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(2-methoxyethylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCCOC MPAYZJKTQWPELV-UHFFFAOYSA-N 0.000 claims description 2
- MINOHQQVIKZUBZ-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(trifluoromethyl)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1C(F)(F)F MINOHQQVIKZUBZ-UHFFFAOYSA-N 0.000 claims description 2
- 206010070606 Post stroke depression Diseases 0.000 claims description 2
- DWAVARUDIVSTBG-UHFFFAOYSA-N [1,3]dioxolo[4,5-g]quinoline Chemical group C1=CN=C2C=C(OCO3)C3=CC2=C1 DWAVARUDIVSTBG-UHFFFAOYSA-N 0.000 claims description 2
- GNAZSOBKJRSETJ-UHFFFAOYSA-N [1-(acetamidomethyl)-4-[[2-(ethylamino)-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxyisoquinolin-3-yl] acetate Chemical compound COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCC)=C(OC(C)=O)N=C(CNC(C)=O)C2=C1 GNAZSOBKJRSETJ-UHFFFAOYSA-N 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- NCDVSIWWXGWTKU-UHFFFAOYSA-N n-[2-[[3-[(1-ethyl-6,7-dimethoxy-3-oxo-2h-isoquinolin-4-yl)methyl]-6-methoxyquinolin-2-yl]amino]ethyl]acetamide;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCCNC(C)=O NCDVSIWWXGWTKU-UHFFFAOYSA-N 0.000 claims description 2
- RXQOVSGSVHFVNW-UHFFFAOYSA-N n-[2-[[3-[(6,7-dimethoxy-1-methyl-3-oxo-2h-isoquinolin-4-yl)methyl]-6-methoxyquinolin-2-yl]amino]ethyl]acetamide;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC=3C(NCCNC(C)=O)=NC4=CC=C(C=C4C=3)OC)=C(O)N=C(C)C2=C1 RXQOVSGSVHFVNW-UHFFFAOYSA-N 0.000 claims description 2
- VSRPFDAROAUHNM-UHFFFAOYSA-N n-[2-[[3-[(6,7-dimethoxy-3-oxo-1-propyl-2h-isoquinolin-4-yl)methyl]-6-ethoxyquinolin-2-yl]amino]ethyl]acetamide;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OCC)=CC=C2N=C1NCCNC(C)=O VSRPFDAROAUHNM-UHFFFAOYSA-N 0.000 claims description 2
- PNPHYPDGACNKKG-UHFFFAOYSA-N n-[2-[[6-(cyclopropylmethoxy)-3-[(1-ethyl-6,7-dimethoxy-3-oxo-2h-isoquinolin-4-yl)methyl]quinolin-2-yl]amino]ethyl]acetamide;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC(C(=NC1=CC=2)NCCNC(C)=O)=CC1=CC=2OCC1CC1 PNPHYPDGACNKKG-UHFFFAOYSA-N 0.000 claims description 2
- KWOBCKDHUOUKGR-UHFFFAOYSA-N n-[2-[[6-(cyclopropylmethoxy)-3-[(6,7-dimethoxy-3-oxo-1-propyl-2h-isoquinolin-4-yl)methyl]quinolin-2-yl]amino]ethyl]acetamide;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC(C(=NC1=CC=2)NCCNC(C)=O)=CC1=CC=2OCC1CC1 KWOBCKDHUOUKGR-UHFFFAOYSA-N 0.000 claims description 2
- DXEBICMERHGPMP-UHFFFAOYSA-N n-[[4-[[2-(ethylamino)-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-3-oxo-2h-isoquinolin-1-yl]methyl]acetamide;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCC)=C(O)N=C(CNC(C)=O)C2=C1 DXEBICMERHGPMP-UHFFFAOYSA-N 0.000 claims description 2
- SPHMNIOCRXGFAR-UHFFFAOYSA-N n-[[4-[[2-(ethylamino)-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-3-oxo-2h-isoquinolin-1-yl]methyl]methanesulfonamide;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCC)=C(O)N=C(CNS(C)(=O)=O)C2=C1 SPHMNIOCRXGFAR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 208000024732 dysthymic disease Diseases 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 101710138657 Neurotoxin Proteins 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 239000002581 neurotoxin Substances 0.000 claims 2
- 231100000618 neurotoxin Toxicity 0.000 claims 2
- 231100000572 poisoning Toxicity 0.000 claims 2
- 230000000607 poisoning effect Effects 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 claims 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 71
- 208000015114 central nervous system disease Diseases 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 670
- 239000000460 chlorine Substances 0.000 description 303
- 239000007787 solid Substances 0.000 description 277
- 239000000243 solution Substances 0.000 description 251
- 239000000203 mixture Substances 0.000 description 229
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 166
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 151
- 238000005160 1H NMR spectroscopy Methods 0.000 description 123
- 238000004128 high performance liquid chromatography Methods 0.000 description 122
- 230000014759 maintenance of location Effects 0.000 description 121
- 238000001514 detection method Methods 0.000 description 120
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 113
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 111
- 239000012267 brine Substances 0.000 description 111
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 111
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 105
- 238000002844 melting Methods 0.000 description 104
- 230000008018 melting Effects 0.000 description 104
- 239000011734 sodium Substances 0.000 description 103
- 238000004440 column chromatography Methods 0.000 description 97
- 229910004298 SiO 2 Inorganic materials 0.000 description 93
- 239000003480 eluent Substances 0.000 description 92
- 239000012458 free base Substances 0.000 description 90
- 239000011541 reaction mixture Substances 0.000 description 89
- 235000019439 ethyl acetate Nutrition 0.000 description 75
- 238000001816 cooling Methods 0.000 description 74
- 238000002360 preparation method Methods 0.000 description 62
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 60
- 239000012074 organic phase Substances 0.000 description 53
- 229940123773 Phosphodiesterase 10A inhibitor Drugs 0.000 description 43
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 42
- 238000003756 stirring Methods 0.000 description 41
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- 239000012044 organic layer Substances 0.000 description 37
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 36
- 238000001704 evaporation Methods 0.000 description 36
- 230000008020 evaporation Effects 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 238000000354 decomposition reaction Methods 0.000 description 32
- 239000003039 volatile agent Substances 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 30
- 238000000746 purification Methods 0.000 description 29
- 238000001035 drying Methods 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- KJXMVLDOJZNMDG-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one Chemical compound O=C1NC(C)=C2C=C(OC)C(OC)=CC2=C1 KJXMVLDOJZNMDG-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- 208000020016 psychiatric disease Diseases 0.000 description 17
- 229920006395 saturated elastomer Polymers 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- DCVWACZNVRBNJN-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-2h-isoquinolin-3-one Chemical compound C1=C(OC)C(OC)=CC2=C(CC)NC(=O)C=C21 DCVWACZNVRBNJN-UHFFFAOYSA-N 0.000 description 14
- AJEWHZOWLOTHDX-UHFFFAOYSA-N 6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one Chemical compound C1=C(OC)C(OC)=CC2=C(CCC)NC(=O)C=C21 AJEWHZOWLOTHDX-UHFFFAOYSA-N 0.000 description 14
- 239000008346 aqueous phase Substances 0.000 description 14
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 12
- 208000012902 Nervous system disease Diseases 0.000 description 12
- 208000025966 Neurological disease Diseases 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- TZQOMBXDCIPJKW-UHFFFAOYSA-N 2-chloro-6-methoxyquinoline-3-carbaldehyde Chemical compound N1=C(Cl)C(C=O)=CC2=CC(OC)=CC=C21 TZQOMBXDCIPJKW-UHFFFAOYSA-N 0.000 description 11
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 11
- 208000027099 Paranoid disease Diseases 0.000 description 11
- 201000002545 drug psychosis Diseases 0.000 description 11
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 10
- 239000012279 sodium borohydride Substances 0.000 description 10
- 229910000033 sodium borohydride Inorganic materials 0.000 description 10
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 235000019502 Orange oil Nutrition 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 239000010502 orange oil Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000000926 neurological effect Effects 0.000 description 8
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 230000036506 anxiety Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical class OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- CHFYFNPAMTXBNW-UHFFFAOYSA-N 6-methoxy-2-(propan-2-ylamino)quinoline-3-carbaldehyde Chemical compound N1=C(NC(C)C)C(C=O)=CC2=CC(OC)=CC=C21 CHFYFNPAMTXBNW-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000000626 neurodegenerative effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- KXYNLLGPBDUAHW-UHFFFAOYSA-N quinolin-4-ylmethanol Chemical compound C1=CC=C2C(CO)=CC=NC2=C1 KXYNLLGPBDUAHW-UHFFFAOYSA-N 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- JZGBWWGJXZKUFG-UHFFFAOYSA-N 3-(chloromethyl)-7-methoxyquinoline;hydrochloride Chemical compound Cl.C1=C(CCl)C=NC2=CC(OC)=CC=C21 JZGBWWGJXZKUFG-UHFFFAOYSA-N 0.000 description 5
- XWGZIWMTRRHICO-UHFFFAOYSA-N 4-[(3-bromophenyl)methyl]-1-ethyl-6,7-dimethoxy-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC=CC(Br)=C1 XWGZIWMTRRHICO-UHFFFAOYSA-N 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- 108010044467 Isoenzymes Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 208000010877 cognitive disease Diseases 0.000 description 5
- 206010015037 epilepsy Diseases 0.000 description 5
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 5
- DILOFCBIBDMHAY-UHFFFAOYSA-N methyl 2-(3,4-dimethoxyphenyl)acetate Chemical compound COC(=O)CC1=CC=C(OC)C(OC)=C1 DILOFCBIBDMHAY-UHFFFAOYSA-N 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- GIFOQCQVDHKICV-UHFFFAOYSA-N 2-(chloromethyl)dibenzofuran Chemical compound C1=CC=C2C3=CC(CCl)=CC=C3OC2=C1 GIFOQCQVDHKICV-UHFFFAOYSA-N 0.000 description 4
- SSSBTEMRIAMJDU-UHFFFAOYSA-N 3-(chloromethyl)-6-ethoxy-n-ethylquinolin-2-amine;hydrochloride Chemical compound Cl.C1=C(OCC)C=C2C=C(CCl)C(NCC)=NC2=C1 SSSBTEMRIAMJDU-UHFFFAOYSA-N 0.000 description 4
- BUDPBFOJKNOVPB-UHFFFAOYSA-N 3-(chloromethyl)-6-methoxy-n-(2,2,2-trifluoroethyl)quinolin-2-amine;hydrochloride Chemical compound Cl.N1=C(NCC(F)(F)F)C(CCl)=CC2=CC(OC)=CC=C21 BUDPBFOJKNOVPB-UHFFFAOYSA-N 0.000 description 4
- BBGKRQZJENZWJC-UHFFFAOYSA-N 3-(chloromethyl)-6-methoxy-n-propan-2-ylquinolin-2-amine;hydrochloride Chemical compound Cl.N1=C(NC(C)C)C(CCl)=CC2=CC(OC)=CC=C21 BBGKRQZJENZWJC-UHFFFAOYSA-N 0.000 description 4
- JPPQNEXECYBSFR-UHFFFAOYSA-N 4-[(6-bromopyridin-2-yl)methyl]-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one Chemical compound C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC1=CC=CC(Br)=N1 JPPQNEXECYBSFR-UHFFFAOYSA-N 0.000 description 4
- HWTCAPGPTURLDC-UHFFFAOYSA-N 5-ethoxyquinoline-3-carbaldehyde Chemical compound C1=C(C=O)C=C2C(OCC)=CC=CC2=N1 HWTCAPGPTURLDC-UHFFFAOYSA-N 0.000 description 4
- BTEUJVGHGXANHO-UHFFFAOYSA-N 6,7-dimethoxy-1-propan-2-yl-2h-isoquinolin-3-one Chemical compound OC1=NC(C(C)C)=C2C=C(OC)C(OC)=CC2=C1 BTEUJVGHGXANHO-UHFFFAOYSA-N 0.000 description 4
- BAUQSXNPDVKKHM-UHFFFAOYSA-N 7-ethoxyquinoline-3-carbaldehyde Chemical compound C1=C(C=O)C=NC2=CC(OCC)=CC=C21 BAUQSXNPDVKKHM-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 4
- INXBUCOUTAVFQJ-UHFFFAOYSA-N [6-methoxy-2-(propan-2-ylamino)quinolin-3-yl]methanol Chemical compound N1=C(NC(C)C)C(CO)=CC2=CC(OC)=CC=C21 INXBUCOUTAVFQJ-UHFFFAOYSA-N 0.000 description 4
- SEWYVXQCYYVMQR-UHFFFAOYSA-N [6-methoxy-2-(propylamino)quinolin-3-yl]methanol Chemical compound C1=C(OC)C=C2C=C(CO)C(NCCC)=NC2=C1 SEWYVXQCYYVMQR-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 229940125900 compound 59 Drugs 0.000 description 4
- 239000002532 enzyme inhibitor Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 150000002367 halogens Chemical group 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 150000004841 phenylimidazoles Chemical class 0.000 description 4
- FLGKQMOTLCGOQH-UHFFFAOYSA-N quinolin-3-ylmethanol Chemical compound C1=CC=CC2=CC(CO)=CN=C21 FLGKQMOTLCGOQH-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 150000003333 secondary alcohols Chemical class 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 3
- CCEVCUWXYQEVBX-UHFFFAOYSA-N (7-ethoxyquinolin-3-yl)methanol Chemical compound C1=C(CO)C=NC2=CC(OCC)=CC=C21 CCEVCUWXYQEVBX-UHFFFAOYSA-N 0.000 description 3
- MNYYBAJZIMIOKC-UHFFFAOYSA-N 2-(benzylamino)-6-methoxyquinoline-3-carbaldehyde Chemical compound O=CC1=CC2=CC(OC)=CC=C2N=C1NCC1=CC=CC=C1 MNYYBAJZIMIOKC-UHFFFAOYSA-N 0.000 description 3
- RUHJZSZTSCSTCC-UHFFFAOYSA-N 2-(bromomethyl)naphthalene Chemical compound C1=CC=CC2=CC(CBr)=CC=C21 RUHJZSZTSCSTCC-UHFFFAOYSA-N 0.000 description 3
- SZYQRVQELHTDQL-UHFFFAOYSA-N 2-(dimethylamino)-6-methylquinoline-3-carbaldehyde Chemical compound C1=C(C)C=C2C=C(C=O)C(N(C)C)=NC2=C1 SZYQRVQELHTDQL-UHFFFAOYSA-N 0.000 description 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
- GQSXXDNIECLFIW-UHFFFAOYSA-N 2H-isoquinolin-3-one dihydrochloride Chemical compound C1=CC2=CC(=O)NC=C2C=C1.Cl.Cl GQSXXDNIECLFIW-UHFFFAOYSA-N 0.000 description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 3
- BFNJEZDJNOGZNP-UHFFFAOYSA-N 3-(chloromethyl)-5-methoxyquinoline;hydrochloride Chemical compound Cl.C1=C(CCl)C=C2C(OC)=CC=CC2=N1 BFNJEZDJNOGZNP-UHFFFAOYSA-N 0.000 description 3
- LZNMLSGXIQNPTE-UHFFFAOYSA-N 3-(chloromethyl)-6-methoxy-n-methylquinolin-2-amine;hydrochloride Chemical compound Cl.C1=C(OC)C=C2C=C(CCl)C(NC)=NC2=C1 LZNMLSGXIQNPTE-UHFFFAOYSA-N 0.000 description 3
- SRUUBOWNWDCHAU-UHFFFAOYSA-N 3-(chloromethyl)-6-methoxy-n-propylquinolin-2-amine;hydrochloride Chemical compound Cl.C1=C(OC)C=C2C=C(CCl)C(NCCC)=NC2=C1 SRUUBOWNWDCHAU-UHFFFAOYSA-N 0.000 description 3
- GOKTXWJZQGPGQP-UHFFFAOYSA-N 3-(chloromethyl)-n,6-dimethylquinolin-2-amine;hydrochloride Chemical compound Cl.C1=C(C)C=C2C=C(CCl)C(NC)=NC2=C1 GOKTXWJZQGPGQP-UHFFFAOYSA-N 0.000 description 3
- OXODRSVGVPCCER-UHFFFAOYSA-N 3-(chloromethyl)-n,n,6-trimethylquinolin-2-amine;hydrochloride Chemical compound Cl.C1=C(C)C=C2C=C(CCl)C(N(C)C)=NC2=C1 OXODRSVGVPCCER-UHFFFAOYSA-N 0.000 description 3
- AVUOBSJXJBWEMJ-UHFFFAOYSA-N 3-(chloromethyl)-n-ethyl-6-methoxyquinolin-2-amine;hydrochloride Chemical compound Cl.C1=C(OC)C=C2C=C(CCl)C(NCC)=NC2=C1 AVUOBSJXJBWEMJ-UHFFFAOYSA-N 0.000 description 3
- CMEUOMIRNZOKTQ-UHFFFAOYSA-N 3-(chloromethyl)-n-ethyl-6-methylquinolin-2-amine;hydrochloride Chemical compound Cl.C1=C(C)C=C2C=C(CCl)C(NCC)=NC2=C1 CMEUOMIRNZOKTQ-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 3
- WZPTXNUCUWJSHX-UHFFFAOYSA-N 6-ethoxy-2-(ethylamino)quinoline-3-carbaldehyde Chemical compound C1=C(OCC)C=C2C=C(C=O)C(NCC)=NC2=C1 WZPTXNUCUWJSHX-UHFFFAOYSA-N 0.000 description 3
- SRNIYPOTDOMYCB-UHFFFAOYSA-N 6-methoxy-2-(methylamino)quinoline-3-carbaldehyde Chemical compound C1=C(OC)C=C2C=C(C=O)C(NC)=NC2=C1 SRNIYPOTDOMYCB-UHFFFAOYSA-N 0.000 description 3
- MMFHZOFSIBFRKZ-UHFFFAOYSA-N 6-methoxy-2-(propylamino)quinoline-3-carbaldehyde Chemical compound C1=C(OC)C=C2C=C(C=O)C(NCCC)=NC2=C1 MMFHZOFSIBFRKZ-UHFFFAOYSA-N 0.000 description 3
- ZFHUCNMZYJZVCZ-UHFFFAOYSA-N 6-methyl-2-(methylamino)quinoline-3-carbaldehyde Chemical compound C1=C(C)C=C2C=C(C=O)C(NC)=NC2=C1 ZFHUCNMZYJZVCZ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 3
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- 208000022497 Cocaine-Related disease Diseases 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- CJCYHHKOPWISBT-UHFFFAOYSA-N [2-(ethylamino)-6-methylquinolin-3-yl]methanol Chemical compound C1=C(C)C=C2C=C(CO)C(NCC)=NC2=C1 CJCYHHKOPWISBT-UHFFFAOYSA-N 0.000 description 3
- BIAJOFDBRYKAMF-UHFFFAOYSA-N [6-ethoxy-2-(ethylamino)quinolin-3-yl]methanol Chemical compound C1=C(OCC)C=C2C=C(CO)C(NCC)=NC2=C1 BIAJOFDBRYKAMF-UHFFFAOYSA-N 0.000 description 3
- YUDDNHUUHRRIBT-UHFFFAOYSA-N [6-methoxy-2-(2,2,2-trifluoroethylamino)quinolin-3-yl]methanol Chemical compound N1=C(NCC(F)(F)F)C(CO)=CC2=CC(OC)=CC=C21 YUDDNHUUHRRIBT-UHFFFAOYSA-N 0.000 description 3
- IIOUTFVZYCYTCG-UHFFFAOYSA-N [6-methoxy-2-(methylamino)quinolin-3-yl]methanol Chemical compound C1=C(OC)C=C2C=C(CO)C(NC)=NC2=C1 IIOUTFVZYCYTCG-UHFFFAOYSA-N 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000133 brain stem Anatomy 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 201000006145 cocaine dependence Diseases 0.000 description 3
- 229940125851 compound 27 Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- ZMBVDFRNENAAKX-UHFFFAOYSA-N dibenzofuran-2-ylmethanol Chemical compound C1=CC=C2C3=CC(CO)=CC=C3OC2=C1 ZMBVDFRNENAAKX-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- HSPKIXPRSRGOQK-UHFFFAOYSA-N isoquinolin-5-ylmethanol Chemical compound N1=CC=C2C(CO)=CC=CC2=C1 HSPKIXPRSRGOQK-UHFFFAOYSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- LPGNCWNWVURLBD-UHFFFAOYSA-N n-[2-[(3-formyl-6-methoxyquinolin-2-yl)amino]ethyl]acetamide Chemical compound N1=C(NCCNC(C)=O)C(C=O)=CC2=CC(OC)=CC=C21 LPGNCWNWVURLBD-UHFFFAOYSA-N 0.000 description 3
- MTWGZLQVRLFUKT-UHFFFAOYSA-N n-[2-[[3-(chloromethyl)-6-methoxyquinolin-2-yl]amino]ethyl]acetamide;hydrochloride Chemical compound Cl.N1=C(NCCNC(C)=O)C(CCl)=CC2=CC(OC)=CC=C21 MTWGZLQVRLFUKT-UHFFFAOYSA-N 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical class C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- LDLSAIBZQUZWTH-UHFFFAOYSA-N (5-ethoxyquinolin-3-yl)methanol Chemical compound C1=C(CO)C=C2C(OCC)=CC=CC2=N1 LDLSAIBZQUZWTH-UHFFFAOYSA-N 0.000 description 2
- VOBHVMILCMPOJC-UHFFFAOYSA-N (5-methoxyquinolin-3-yl)methanol Chemical compound C1=C(CO)C=C2C(OC)=CC=CC2=N1 VOBHVMILCMPOJC-UHFFFAOYSA-N 0.000 description 2
- BTRMZBFQCRUSBI-UHFFFAOYSA-N (7-methoxyquinolin-3-yl)methanol Chemical compound C1=C(CO)C=NC2=CC(OC)=CC=C21 BTRMZBFQCRUSBI-UHFFFAOYSA-N 0.000 description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 2
- YNHQXCDMFQRWLP-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[(7-methoxyquinolin-3-yl)methyl]-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CN=C(C=C(OC)C=C2)C2=C1 YNHQXCDMFQRWLP-UHFFFAOYSA-N 0.000 description 2
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 2
- WDETYCRYUBGKCE-UHFFFAOYSA-N 2-(chloromethyl)quinolin-1-ium;chloride Chemical compound Cl.C1=CC=CC2=NC(CCl)=CC=C21 WDETYCRYUBGKCE-UHFFFAOYSA-N 0.000 description 2
- UUGDBLXMSLEBAL-UHFFFAOYSA-N 2-(ethylamino)-6-methoxyquinoline-3-carbaldehyde Chemical compound C1=C(OC)C=C2C=C(C=O)C(NCC)=NC2=C1 UUGDBLXMSLEBAL-UHFFFAOYSA-N 0.000 description 2
- YFVWCFVZWWQNBO-UHFFFAOYSA-N 2-(ethylamino)-6-methylquinoline-3-carbaldehyde Chemical compound C1=C(C)C=C2C=C(C=O)C(NCC)=NC2=C1 YFVWCFVZWWQNBO-UHFFFAOYSA-N 0.000 description 2
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 2
- BNLBYGHJJYCBEJ-UHFFFAOYSA-N 2-chloro-6-ethoxyquinoline-3-carbaldehyde Chemical compound N1=C(Cl)C(C=O)=CC2=CC(OCC)=CC=C21 BNLBYGHJJYCBEJ-UHFFFAOYSA-N 0.000 description 2
- QWDRTANOQNQDMU-UHFFFAOYSA-N 2-chloro-6-hydroxyquinoline-3-carbaldehyde Chemical compound N1=C(Cl)C(C=O)=CC2=CC(O)=CC=C21 QWDRTANOQNQDMU-UHFFFAOYSA-N 0.000 description 2
- FSLNYYZJXMGKHK-UHFFFAOYSA-N 2-chloro-6-methylquinoline-3-carbaldehyde Chemical compound N1=C(Cl)C(C=O)=CC2=CC(C)=CC=C21 FSLNYYZJXMGKHK-UHFFFAOYSA-N 0.000 description 2
- GYPOFOQUZZUVQL-UHFFFAOYSA-N 2h-isoquinolin-3-one Chemical compound C1=CC=C2C=NC(O)=CC2=C1 GYPOFOQUZZUVQL-UHFFFAOYSA-N 0.000 description 2
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- OOTQZLQSAKCFQS-UHFFFAOYSA-N 3-(chloromethyl)-6-methoxy-1-propan-2-yl-2H-quinoline Chemical compound ClCC=1CN(C2=CC=C(C=C2C=1)OC)C(C)C OOTQZLQSAKCFQS-UHFFFAOYSA-N 0.000 description 2
- KUFNCRLQPVFMHC-UHFFFAOYSA-N 3-(chloromethyl)-7-ethoxyquinoline;hydrochloride Chemical compound Cl.C1=C(CCl)C=NC2=CC(OCC)=CC=C21 KUFNCRLQPVFMHC-UHFFFAOYSA-N 0.000 description 2
- KZLDLNZHGOGVAU-UHFFFAOYSA-N 3-(chloromethyl)quinoline;hydrochloride Chemical compound Cl.C1=CC=CC2=CC(CCl)=CN=C21 KZLDLNZHGOGVAU-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- YCSBVZQGDUCJIN-UHFFFAOYSA-N 4-(chloromethyl)quinoline;hydrochloride Chemical compound Cl.C1=CC=C2C(CCl)=CC=NC2=C1 YCSBVZQGDUCJIN-UHFFFAOYSA-N 0.000 description 2
- UWMFXMIHNIGVKF-UHFFFAOYSA-N 4-(dibenzofuran-2-ylmethyl)-1-ethyl-6,7-dimethoxy-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC=C(OC=2C3=CC=CC=2)C3=C1 UWMFXMIHNIGVKF-UHFFFAOYSA-N 0.000 description 2
- YPZCTRLKNWAEEI-UHFFFAOYSA-N 4-(dibenzofuran-2-ylmethyl)-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC=C(OC=2C3=CC=CC=2)C3=C1 YPZCTRLKNWAEEI-UHFFFAOYSA-N 0.000 description 2
- NVDULXLQIYUPPW-UHFFFAOYSA-N 4-(isoquinolin-5-ylmethyl)-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.N1=CC=C2C(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=CC2=C1 NVDULXLQIYUPPW-UHFFFAOYSA-N 0.000 description 2
- IVZZKWVKZDJORU-UHFFFAOYSA-N 4-[(5-bromopyridin-3-yl)methyl]-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one Chemical compound C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC1=CN=CC(Br)=C1 IVZZKWVKZDJORU-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- VQDMURIWGCFWKV-UHFFFAOYSA-N 5-methoxyquinoline-3-carbaldehyde Chemical compound C1=C(C=O)C=C2C(OC)=CC=CC2=N1 VQDMURIWGCFWKV-UHFFFAOYSA-N 0.000 description 2
- XZLIYCQRASOFQM-UHFFFAOYSA-N 5h-imidazo[4,5-d]triazine Chemical class N1=NC=C2NC=NC2=N1 XZLIYCQRASOFQM-UHFFFAOYSA-N 0.000 description 2
- GZNZXNRRUAJXKK-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-(naphthalen-2-ylmethyl)-2h-isoquinolin-3-one Chemical compound C1=CC=CC2=CC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=C21 GZNZXNRRUAJXKK-UHFFFAOYSA-N 0.000 description 2
- JOUWTJUNTDKBBC-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-(quinolin-3-ylmethyl)-2h-isoquinolin-3-one Chemical compound C1=CC=CC2=CC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CN=C21 JOUWTJUNTDKBBC-UHFFFAOYSA-N 0.000 description 2
- NKZHEVTWRDRQNI-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[(5-phenylpyridin-3-yl)methyl]-2h-isoquinolin-3-one Chemical compound C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC(C=1)=CN=CC=1C1=CC=CC=C1 NKZHEVTWRDRQNI-UHFFFAOYSA-N 0.000 description 2
- HPRJMGWMBHKSSB-UHFFFAOYSA-N 6,7-dimethoxy-4-[(7-methoxyquinolin-3-yl)methyl]-1-methyl-2h-isoquinolin-3-one Chemical compound COC1=C(OC)C=C2C(CC3=CC4=CC=C(C=C4N=C3)OC)=C(O)N=C(C)C2=C1 HPRJMGWMBHKSSB-UHFFFAOYSA-N 0.000 description 2
- JHGTUQCBTCXURT-UHFFFAOYSA-N 6-methoxy-2-(2,2,2-trifluoroethylamino)quinoline-3-carbaldehyde Chemical compound N1=C(NCC(F)(F)F)C(C=O)=CC2=CC(OC)=CC=C21 JHGTUQCBTCXURT-UHFFFAOYSA-N 0.000 description 2
- WBGGEFMEZDJKID-UHFFFAOYSA-N 7-methoxyquinoline-3-carbaldehyde Chemical compound C1=C(C=O)C=NC2=CC(OC)=CC=C21 WBGGEFMEZDJKID-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 108010078321 Guanylate Cyclase Proteins 0.000 description 2
- 102000014469 Guanylate cyclase Human genes 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000019430 Motor disease Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000026251 Opioid-Related disease Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 208000034247 Pattern dystrophy Diseases 0.000 description 2
- 206010034912 Phobia Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000013200 Stress disease Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- RMESGCIFAGYXOS-UHFFFAOYSA-N [2-(benzylamino)-6-methoxyquinolin-3-yl]methanol Chemical compound OCC1=CC2=CC(OC)=CC=C2N=C1NCC1=CC=CC=C1 RMESGCIFAGYXOS-UHFFFAOYSA-N 0.000 description 2
- REYYLTHRXCHJKH-UHFFFAOYSA-N [2-(dimethylamino)-6-methylquinolin-3-yl]methanol Chemical compound C1=C(C)C=C2C=C(CO)C(N(C)C)=NC2=C1 REYYLTHRXCHJKH-UHFFFAOYSA-N 0.000 description 2
- KQCONMPYPQCDCW-UHFFFAOYSA-N [2-(ethylamino)-6-methoxyquinolin-3-yl]methanol Chemical compound C1=C(OC)C=C2C=C(CO)C(NCC)=NC2=C1 KQCONMPYPQCDCW-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- 125000005997 bromomethyl group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000000259 cinnolinyl group Chemical class N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000000609 ganglia Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002390 heteroarenes Chemical class 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- WUAXWQRULBZETB-UHFFFAOYSA-N homoveratric acid Chemical compound COC1=CC=C(CC(O)=O)C=C1OC WUAXWQRULBZETB-UHFFFAOYSA-N 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- WGYMXASRWCYKQR-UHFFFAOYSA-N imidazo[1,5-a]quinoxaline Chemical class C1=CC=C2N3C=NC=C3C=NC2=C1 WGYMXASRWCYKQR-UHFFFAOYSA-N 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- XIRLIZNMBKEUDD-UHFFFAOYSA-N isoquinolin-6-ylmethanol Chemical compound C1=NC=CC2=CC(CO)=CC=C21 XIRLIZNMBKEUDD-UHFFFAOYSA-N 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- WBOGYPHTFMCSLJ-UHFFFAOYSA-N methyl 2-(2-acetyl-4,5-dimethoxyphenyl)-3-(5-methoxyquinolin-3-yl)propanoate Chemical compound C=1N=C2C=CC=C(OC)C2=CC=1CC(C(=O)OC)C1=CC(OC)=C(OC)C=C1C(C)=O WBOGYPHTFMCSLJ-UHFFFAOYSA-N 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- WJVXZRIXWAEOKW-UHFFFAOYSA-N n-[2-[[3-(hydroxymethyl)-6-methoxyquinolin-2-yl]amino]ethyl]acetamide Chemical compound N1=C(NCCNC(C)=O)C(CO)=CC2=CC(OC)=CC=C21 WJVXZRIXWAEOKW-UHFFFAOYSA-N 0.000 description 2
- SILNLTNRGUIQHP-UHFFFAOYSA-N n-[2-[[3-[(6,7-dimethoxy-3-oxo-1-propyl-2h-isoquinolin-4-yl)methyl]-6-methoxyquinolin-2-yl]amino]ethyl]acetamide Chemical compound C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCCNC(C)=O SILNLTNRGUIQHP-UHFFFAOYSA-N 0.000 description 2
- CEAXLAHAGGVLQO-UHFFFAOYSA-N n-benzyl-3-(chloromethyl)-6-methoxyquinolin-2-amine;hydrochloride Chemical compound Cl.ClCC1=CC2=CC(OC)=CC=C2N=C1NCC1=CC=CC=C1 CEAXLAHAGGVLQO-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 201000005040 opiate dependence Diseases 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 208000019899 phobic disease Diseases 0.000 description 2
- 108091008695 photoreceptors Proteins 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920005990 polystyrene resin Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 description 2
- 150000003246 quinazolines Chemical class 0.000 description 2
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 2
- RYGIHSLRMNXWCN-UHFFFAOYSA-N quinoline-3-carbaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CN=C21 RYGIHSLRMNXWCN-UHFFFAOYSA-N 0.000 description 2
- MGCGJBXTNWUHQE-UHFFFAOYSA-N quinoline-4-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CC=NC2=C1 MGCGJBXTNWUHQE-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- XDDGKNRSCDEWBR-UHFFFAOYSA-N (6-bromopyridin-2-yl)methanol Chemical compound OCC1=CC=CC(Br)=N1 XDDGKNRSCDEWBR-UHFFFAOYSA-N 0.000 description 1
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 1
- CPIGBCFBFZSCQI-UHFFFAOYSA-N 1-(bromomethyl)-4-phenoxybenzene Chemical compound C1=CC(CBr)=CC=C1OC1=CC=CC=C1 CPIGBCFBFZSCQI-UHFFFAOYSA-N 0.000 description 1
- ZPCJPJQUVRIILS-UHFFFAOYSA-N 1-bromo-3-(bromomethyl)benzene Chemical compound BrCC1=CC=CC(Br)=C1 ZPCJPJQUVRIILS-UHFFFAOYSA-N 0.000 description 1
- OZPXYKLNWTVVJQ-UHFFFAOYSA-N 1-ethyl-4-[[2-(ethylamino)-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-2h-isoquinolin-3-one Chemical compound COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCC)=C(O)N=C(CC)C2=C1 OZPXYKLNWTVVJQ-UHFFFAOYSA-N 0.000 description 1
- WHVSZXAFMNGKFO-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[(3-phenylphenyl)methyl]-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC(C=1)=CC=CC=1C1=CC=CC=C1 WHVSZXAFMNGKFO-UHFFFAOYSA-N 0.000 description 1
- DRAAXALLPLIIEN-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[3-(4-methoxyphenyl)phenyl]methyl]-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC(C=1)=CC=CC=1C1=CC=C(OC)C=C1 DRAAXALLPLIIEN-UHFFFAOYSA-N 0.000 description 1
- GAHLWAGNDOJUEX-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[6-methoxy-2-(2,2,2-trifluoroethylamino)quinolin-3-yl]methyl]-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCC(F)(F)F GAHLWAGNDOJUEX-UHFFFAOYSA-N 0.000 description 1
- YQUDIYLTFMWJTM-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[6-methoxy-2-(methylamino)quinolin-3-yl]methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NC YQUDIYLTFMWJTM-UHFFFAOYSA-N 0.000 description 1
- DBFADHJMUCFLPL-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[6-methoxy-2-(propylamino)quinolin-3-yl]methyl]-2h-isoquinolin-3-one Chemical compound COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCCC)=C(O)N=C(CC)C2=C1 DBFADHJMUCFLPL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- YUADUYQBMVFPNE-UHFFFAOYSA-N 2-bromo-6-(chloromethyl)pyridine;hydrochloride Chemical compound Cl.ClCC1=CC=CC(Br)=N1 YUADUYQBMVFPNE-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- QHKSFEAOENGDFZ-UHFFFAOYSA-N 3,6,7-trimethoxy-1-methyl-4-(naphthalen-2-ylmethyl)isoquinoline Chemical compound C1=CC=CC2=CC(CC=3C(OC)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=C21 QHKSFEAOENGDFZ-UHFFFAOYSA-N 0.000 description 1
- KAXCAEQTBXRFJK-UHFFFAOYSA-N 3-(chloromethyl)-5-ethoxyquinoline;hydrochloride Chemical compound Cl.C1=C(CCl)C=C2C(OCC)=CC=CC2=N1 KAXCAEQTBXRFJK-UHFFFAOYSA-N 0.000 description 1
- AIHRBOUGARUAAV-UHFFFAOYSA-N 3-(chloromethyl)-n-ethyl-6-methoxyquinolin-2-amine Chemical compound C1=C(OC)C=C2C=C(CCl)C(NCC)=NC2=C1 AIHRBOUGARUAAV-UHFFFAOYSA-N 0.000 description 1
- YABDPDLJHFGDTE-UHFFFAOYSA-N 3-[bis[(2-methylpropan-2-yl)oxy]boranyl]aniline Chemical compound CC(C)(C)OB(OC(C)(C)C)C1=CC=CC(N)=C1 YABDPDLJHFGDTE-UHFFFAOYSA-N 0.000 description 1
- CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-aminophenol Chemical compound NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 description 1
- 229940018563 3-aminophenol Drugs 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- YSCQHNAHOLVDHS-UHFFFAOYSA-N 3-ethyl-6-methoxyquinolin-2-amine;hydrochloride Chemical compound Cl.COC1=CC=C2N=C(N)C(CC)=CC2=C1 YSCQHNAHOLVDHS-UHFFFAOYSA-N 0.000 description 1
- MKSOJXSIFTVEIO-UHFFFAOYSA-N 3h-pyrido[2,3-b]pyrazin-4-amine Chemical compound C1=CN=C2N(N)CC=NC2=C1 MKSOJXSIFTVEIO-UHFFFAOYSA-N 0.000 description 1
- KRLKXOLFFQWKPZ-UHFFFAOYSA-N 4-(bromomethyl)pyridine Chemical compound BrCC1=CC=NC=C1 KRLKXOLFFQWKPZ-UHFFFAOYSA-N 0.000 description 1
- CTOHHRUHXXPTIZ-UHFFFAOYSA-N 4-(dibenzofuran-2-ylmethyl)-6,7-dimethoxy-1-propylisoquinolin-3-amine;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(N)=C1CC1=CC=C(OC=2C3=CC=CC=2)C3=C1 CTOHHRUHXXPTIZ-UHFFFAOYSA-N 0.000 description 1
- ALHOOVRBOSPYKQ-UHFFFAOYSA-N 4-(isoquinolin-6-ylmethyl)-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one Chemical compound C1=NC=CC2=CC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=C21 ALHOOVRBOSPYKQ-UHFFFAOYSA-N 0.000 description 1
- USJWNBJAYWGXSY-UHFFFAOYSA-N 4-[(3,4-dimethoxyphenyl)methyl]-3,6,7-trimethoxy-1-methylisoquinoline Chemical compound C1=C(OC)C(OC)=CC=C1CC1=C(OC)N=C(C)C2=CC(OC)=C(OC)C=C12 USJWNBJAYWGXSY-UHFFFAOYSA-N 0.000 description 1
- BKVMDXSVITZTHP-UHFFFAOYSA-N 4-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one Chemical compound C1=C(OC)C(OC)=CC=C1CC1=C(O)N=C(C)C2=CC(OC)=C(OC)C=C12 BKVMDXSVITZTHP-UHFFFAOYSA-N 0.000 description 1
- WDFLJGFOMFMOSP-UHFFFAOYSA-N 4-[(5-ethoxyquinolin-3-yl)methyl]-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one Chemical compound COC1=C(OC)C=C2C(CC3=CN=C4C=CC=C(C4=C3)OCC)=C(O)N=C(C)C2=C1 WDFLJGFOMFMOSP-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- GKUCUJRTHKCIFW-UHFFFAOYSA-N 4-[[2-(dimethylamino)-6-methylquinolin-3-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(C)=CC=C2N=C1N(C)C GKUCUJRTHKCIFW-UHFFFAOYSA-N 0.000 description 1
- BTVHMQIGTGARHO-UHFFFAOYSA-N 4-[[2-(ethylamino)-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCC BTVHMQIGTGARHO-UHFFFAOYSA-N 0.000 description 1
- YKXBEBYXGCQYRD-UHFFFAOYSA-N 4-[[6-(ethylamino)-[1,3]dioxolo[4,5-g]quinolin-7-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC(C(=NC1=C2)NCC)=CC1=CC1=C2OCO1 YKXBEBYXGCQYRD-UHFFFAOYSA-N 0.000 description 1
- YSULUHPMOZYEET-UHFFFAOYSA-N 4-[[6-ethoxy-2-(ethylamino)quinolin-3-yl]methyl]-6,7-dimethoxy-1-propan-2-yl-2h-isoquinolin-3-one Chemical compound COC1=C(OC)C=C2C(CC3=CC4=CC(OCC)=CC=C4N=C3NCC)=C(O)N=C(C(C)C)C2=C1 YSULUHPMOZYEET-UHFFFAOYSA-N 0.000 description 1
- PTIHZUGFJACORJ-UHFFFAOYSA-N 4-[[6-ethoxy-2-(ethylamino)quinolin-3-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OCC)=CC=C2N=C1NCC PTIHZUGFJACORJ-UHFFFAOYSA-N 0.000 description 1
- VIMMTIWARBDYNN-UHFFFAOYSA-N 4-piperidin-1-ylquinazoline Chemical class C1CCCCN1C1=NC=NC2=CC=CC=C12 VIMMTIWARBDYNN-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- KBVRPRVLDOEOSG-UHFFFAOYSA-N 5-(chloromethyl)isoquinoline;hydrochloride Chemical compound Cl.N1=CC=C2C(CCl)=CC=CC2=C1 KBVRPRVLDOEOSG-UHFFFAOYSA-N 0.000 description 1
- JJYAVRXAAVFQJJ-UHFFFAOYSA-N 5-(chloromethyl)quinoline;hydrochloride Chemical compound Cl.C1=CC=C2C(CCl)=CC=CC2=N1 JJYAVRXAAVFQJJ-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- 150000000565 5-membered heterocyclic compounds Chemical class 0.000 description 1
- 150000005513 6,7-dialkoxyisoquinolines Chemical class 0.000 description 1
- ZDQOTYWKYWVADY-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-(pyridin-4-ylmethyl)-2h-isoquinolin-3-one Chemical compound C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC1=CC=NC=C1 ZDQOTYWKYWVADY-UHFFFAOYSA-N 0.000 description 1
- LFYTZWVONFSGJX-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-(quinolin-2-ylmethyl)-2h-isoquinolin-3-one Chemical compound C1=CC=CC2=NC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=C21 LFYTZWVONFSGJX-UHFFFAOYSA-N 0.000 description 1
- TVIZTBGBPYIUHK-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-(quinolin-2-ylmethyl)-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C1=CC=CC2=NC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=C21 TVIZTBGBPYIUHK-UHFFFAOYSA-N 0.000 description 1
- MOUGXHDNRJJKRN-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-(quinolin-6-ylmethyl)-2h-isoquinolin-3-one Chemical compound N1=CC=CC2=CC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=C21 MOUGXHDNRJJKRN-UHFFFAOYSA-N 0.000 description 1
- TVJKXTCTYLBZFM-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[(3-phenoxyphenyl)methyl]-2h-isoquinolin-3-one Chemical compound C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC(C=1)=CC=CC=1OC1=CC=CC=C1 TVJKXTCTYLBZFM-UHFFFAOYSA-N 0.000 description 1
- XWATTXVDJWYJSF-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[(4-phenoxyphenyl)methyl]-2h-isoquinolin-3-one Chemical compound C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC(C=C1)=CC=C1OC1=CC=CC=C1 XWATTXVDJWYJSF-UHFFFAOYSA-N 0.000 description 1
- IEDXHPIWGCDDEB-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[(6-phenylpyridin-2-yl)methyl]-2h-isoquinolin-3-one Chemical compound C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC(N=1)=CC=CC=1C1=CC=CC=C1 IEDXHPIWGCDDEB-UHFFFAOYSA-N 0.000 description 1
- RRRVIAQOQMAHOQ-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[(6-pyridin-4-ylpyridin-2-yl)methyl]-2h-isoquinolin-3-one Chemical compound C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC(N=1)=CC=CC=1C1=CC=NC=C1 RRRVIAQOQMAHOQ-UHFFFAOYSA-N 0.000 description 1
- SVBAVLKSWAONTO-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[[6-methyl-2-(methylamino)quinolin-3-yl]methyl]-2h-isoquinolin-3-one Chemical compound COC1=C(OC)C=C2C(CC3=CC4=CC(C)=CC=C4N=C3NC)=C(O)N=C(C)C2=C1 SVBAVLKSWAONTO-UHFFFAOYSA-N 0.000 description 1
- IRUZWFZHBKSSKB-UHFFFAOYSA-N 6,7-dimethoxy-4-[(5-methoxyquinolin-3-yl)methyl]-1-methyl-2h-isoquinolin-3-one Chemical compound C1=CC=C(OC)C2=CC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CN=C21 IRUZWFZHBKSSKB-UHFFFAOYSA-N 0.000 description 1
- FQHVBUYNIPKVQS-UHFFFAOYSA-N 6,7-dimethoxy-4-[(7-methoxyquinolin-3-yl)methyl]-1-propyl-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CN=C(C=C(OC)C=C2)C2=C1 FQHVBUYNIPKVQS-UHFFFAOYSA-N 0.000 description 1
- PZGMSPJSIGMXQV-UHFFFAOYSA-N 6,7-dimethoxy-4-[[5-(4-methoxyphenyl)pyridin-3-yl]methyl]-1-methyl-2h-isoquinolin-3-one Chemical compound C1=CC(OC)=CC=C1C1=CN=CC(CC=2C3=CC(OC)=C(OC)C=C3C(C)=NC=2O)=C1 PZGMSPJSIGMXQV-UHFFFAOYSA-N 0.000 description 1
- AVSVIHBZUKCMSC-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-(4-methoxyphenyl)pyridin-2-yl]methyl]-1-methyl-2h-isoquinolin-3-one Chemical compound C1=CC(OC)=CC=C1C1=CC=CC(CC=2C3=CC(OC)=C(OC)C=C3C(C)=NC=2O)=N1 AVSVIHBZUKCMSC-UHFFFAOYSA-N 0.000 description 1
- PUECNZWNMCIENI-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(2,2,2-trifluoroethylamino)quinolin-3-yl]methyl]-1-propan-2-yl-2h-isoquinolin-3-one Chemical compound COC1=C(OC)C=C2C(CC=3C(NCC(F)(F)F)=NC4=CC=C(C=C4C=3)OC)=C(O)N=C(C(C)C)C2=C1 PUECNZWNMCIENI-UHFFFAOYSA-N 0.000 description 1
- USIMWRYQHAXOHD-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(2,2,2-trifluoroethylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCC(F)(F)F USIMWRYQHAXOHD-UHFFFAOYSA-N 0.000 description 1
- FWQGMVUNVROMOR-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(methylamino)quinolin-3-yl]methyl]-1-methyl-2h-isoquinolin-3-one Chemical compound COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NC)=C(O)N=C(C)C2=C1 FWQGMVUNVROMOR-UHFFFAOYSA-N 0.000 description 1
- YXFFDHPNVCNTLT-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(methylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NC YXFFDHPNVCNTLT-UHFFFAOYSA-N 0.000 description 1
- QSVUKJHTXXITSE-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(propan-2-ylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NC(C)C QSVUKJHTXXITSE-UHFFFAOYSA-N 0.000 description 1
- CHGWXIVSYAVUFC-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(propylamino)quinolin-3-yl]methyl]-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCCC)=C(O)N=C(C)C2=C1 CHGWXIVSYAVUFC-UHFFFAOYSA-N 0.000 description 1
- GCXKZJCQYWFVAJ-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methyl-2-(methylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(C)=CC=C2N=C1NC GCXKZJCQYWFVAJ-UHFFFAOYSA-N 0.000 description 1
- OHMSEJVQIVENNA-UHFFFAOYSA-N 6-(chloromethyl)isoquinoline;hydrochloride Chemical compound Cl.C1=NC=CC2=CC(CCl)=CC=C21 OHMSEJVQIVENNA-UHFFFAOYSA-N 0.000 description 1
- SFSJEEURWPMFDR-UHFFFAOYSA-N 6-(chloromethyl)quinolin-1-ium;chloride Chemical compound Cl.N1=CC=CC2=CC(CCl)=CC=C21 SFSJEEURWPMFDR-UHFFFAOYSA-N 0.000 description 1
- 150000000644 6-membered heterocyclic compounds Chemical class 0.000 description 1
- VCQPAWCBYPFXIQ-UHFFFAOYSA-N 6-methoxy-2-(trifluoromethyl)quinoline-3-carbaldehyde Chemical compound N1=C(C(F)(F)F)C(C=O)=CC2=CC(OC)=CC=C21 VCQPAWCBYPFXIQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- PVFOHMXILQEIHX-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-bromophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Br PVFOHMXILQEIHX-UHFFFAOYSA-N 0.000 description 1
- USVZHTBPMMSRHY-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-chlorophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Cl USVZHTBPMMSRHY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- UXYHZIYEDDINQH-UHFFFAOYSA-N C1=CNC2=C3C=NN=C3C=CC2=C1 Chemical class C1=CNC2=C3C=NN=C3C=CC2=C1 UXYHZIYEDDINQH-UHFFFAOYSA-N 0.000 description 1
- ZBIOCXHDOWPOPK-UHFFFAOYSA-N CCCN1CC(=CC2=C1C=CC(=C2)OC)CCl Chemical compound CCCN1CC(=CC2=C1C=CC(=C2)OC)CCl ZBIOCXHDOWPOPK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- DWGWCWDDNTVOGF-UHFFFAOYSA-N Cl.Cl.Cl.Cl.Cl.Cl Chemical compound Cl.Cl.Cl.Cl.Cl.Cl DWGWCWDDNTVOGF-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000001351 Epiretinal Membrane Diseases 0.000 description 1
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101001098858 Homo sapiens cGMP-dependent 3',5'-cyclic phosphodiesterase Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000031471 Macular fibrosis Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-O Methylammonium ion Chemical compound [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- GNOYRJIXSUNXIH-UHFFFAOYSA-N N1=CNC2=C3C=NN=C3C=CC2=C1 Chemical class N1=CNC2=C3C=NN=C3C=CC2=C1 GNOYRJIXSUNXIH-UHFFFAOYSA-N 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 208000004224 Opium Dependence Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000002367 Retinal Perforations Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000036750 Schizophrenia, residual type Diseases 0.000 description 1
- 208000024791 Schizotypal Personality disease Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000027073 Stargardt disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- FUKMVUQIGDVHKO-UHFFFAOYSA-N [6-methyl-2-(methylamino)quinolin-3-yl]methanol Chemical compound C1=C(C)C=C2C=C(CO)C(NC)=NC2=C1 FUKMVUQIGDVHKO-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 208000018300 basal ganglia disease Diseases 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-O butylazanium Chemical compound CCCC[NH3+] HQABUPZFAYXKJW-UHFFFAOYSA-O 0.000 description 1
- 102100038953 cGMP-dependent 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 229940018557 citraconic acid Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- OVJMIWIVPWPZMN-UHFFFAOYSA-N dibenzofuran-2-carbaldehyde Chemical compound C1=CC=C2C3=CC(C=O)=CC=C3OC2=C1 OVJMIWIVPWPZMN-UHFFFAOYSA-N 0.000 description 1
- 150000004826 dibenzofurans Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 102000054918 human PDE10A Human genes 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- PSXRWZBTVAZNSF-UHFFFAOYSA-N hydron;quinoline;chloride Chemical compound Cl.N1=CC=CC2=CC=CC=C21 PSXRWZBTVAZNSF-UHFFFAOYSA-N 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000005236 imidazo[1,2-a]pyrazines Chemical class 0.000 description 1
- 150000004942 imidazo[1,2-b]pyridazines Chemical class 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- LSACYLWPPQLVSM-UHFFFAOYSA-N isobutyric acid anhydride Chemical compound CC(C)C(=O)OC(=O)C(C)C LSACYLWPPQLVSM-UHFFFAOYSA-N 0.000 description 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 1
- HJHXYSBRTVFEDD-UHFFFAOYSA-N isoquinoline-1-carbonitrile Chemical class C1=CC=C2C(C#N)=NC=CC2=C1 HJHXYSBRTVFEDD-UHFFFAOYSA-N 0.000 description 1
- ILRSABOCKMOFGW-UHFFFAOYSA-N isoquinoline-5-carbaldehyde Chemical compound N1=CC=C2C(C=O)=CC=CC2=C1 ILRSABOCKMOFGW-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000029233 macular holes Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- VITYGZIRYHMYRW-UHFFFAOYSA-N methyl 2-(3,4-dimethoxyphenyl)-3-(5-methoxyquinolin-3-yl)propanoate Chemical compound C=1N=C2C=CC=C(OC)C2=CC=1CC(C(=O)OC)C1=CC=C(OC)C(OC)=C1 VITYGZIRYHMYRW-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- UVPWZEOLHRROQK-UHFFFAOYSA-N methyl isoquinoline-6-carboxylate Chemical compound C1=NC=CC2=CC(C(=O)OC)=CC=C21 UVPWZEOLHRROQK-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- OUQVKRKGTAUJQA-UHFFFAOYSA-N n-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine Chemical compound C1=CC=CC2=C(O)C(C(=O)NCC(=O)O)=NC(Cl)=C21 OUQVKRKGTAUJQA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 208000024817 paranoid personality disease Diseases 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- AFDMODCXODAXLC-UHFFFAOYSA-N phenylmethanimine Chemical class N=CC1=CC=CC=C1 AFDMODCXODAXLC-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- WTYSCLHDMXBMKM-UHFFFAOYSA-N phthalazin-1-amine Chemical class C1=CC=C2C(N)=NN=CC2=C1 WTYSCLHDMXBMKM-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical class OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- JAVXBQKCKGHZHM-TWTPFVCWSA-N propyl (2e,4e)-hexa-2,4-dienoate Chemical compound CCCOC(=O)\C=C\C=C\C JAVXBQKCKGHZHM-TWTPFVCWSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- HBMUMVMGBLMQJT-UHFFFAOYSA-N pyrrolo[2,1-a]isoquinoline Chemical class C12=CC=CC=C2C=CN2C1=CC=C2 HBMUMVMGBLMQJT-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- YQEJIIUSNDZIGO-UHFFFAOYSA-N quinolin-6-ylmethanol Chemical compound N1=CC=CC2=CC(CO)=CC=C21 YQEJIIUSNDZIGO-UHFFFAOYSA-N 0.000 description 1
- ALQUTEKNDPODSS-UHFFFAOYSA-N quinoline-4-carbaldehyde-oxime Natural products C1=CC=C2C(C=NO)=CC=NC2=C1 ALQUTEKNDPODSS-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000014786 regulation of synaptic transmission Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000024725 retina neoplasm Diseases 0.000 description 1
- 201000008933 retinal cancer Diseases 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical class C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 description 1
- 208000016686 tic disease Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161444566P | 2011-02-18 | 2011-02-18 | |
| US61/444,566 | 2011-02-18 | ||
| PCT/US2012/025731 WO2012112946A1 (en) | 2011-02-18 | 2012-02-17 | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510055A true JP2014510055A (ja) | 2014-04-24 |
| JP2014510055A5 JP2014510055A5 (enExample) | 2015-04-09 |
Family
ID=45787353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013554657A Pending JP2014510055A (ja) | 2011-02-18 | 2012-02-17 | ホスホジエステラーゼ１０（ｐｄｅ１０ａ）阻害剤としての置換６，７−ジアルコキシ−３−イソキノリノール誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8772316B2 (enExample) |
| EP (1) | EP2675791B1 (enExample) |
| JP (1) | JP2014510055A (enExample) |
| KR (1) | KR20140009372A (enExample) |
| CN (1) | CN103476757A (enExample) |
| AU (1) | AU2012219316A1 (enExample) |
| BR (1) | BR112013021180A2 (enExample) |
| CA (1) | CA2827724A1 (enExample) |
| CL (1) | CL2013002394A1 (enExample) |
| IL (1) | IL228008A0 (enExample) |
| MX (1) | MX2013009575A (enExample) |
| RU (1) | RU2013142364A (enExample) |
| SG (1) | SG192839A1 (enExample) |
| WO (1) | WO2012112946A1 (enExample) |
| ZA (1) | ZA201306416B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019509267A (ja) * | 2016-02-12 | 2019-04-04 | アステラス製薬株式会社 | テトラヒドロイソキノリン誘導体 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103476757A (zh) | 2011-02-18 | 2013-12-25 | 阿勒根公司 | 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物 |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| JP6272604B2 (ja) * | 2013-12-27 | 2018-01-31 | 日本サプリメント株式会社 | 糖取り込み促進剤 |
| CN104370813A (zh) * | 2014-10-22 | 2015-02-25 | 上海大学 | 异喹啉-6-甲醛的制备方法 |
| ES2837396T3 (es) | 2016-11-23 | 2021-06-30 | Bayer Cropscience Ag | Derivados de 2-[3-(alquilsulfonil)-2H-indazol-2-il]-3H-imidazo[4,5-b]piridina y compuestos similares como pesticidas |
| EA202191554A1 (ru) | 2018-12-03 | 2021-09-02 | Фмк Корпорейшн | Способ получения n-фенилпиразол-1-карбоксамидов |
| CN113376287A (zh) * | 2021-06-15 | 2021-09-10 | 劲牌有限公司 | 基于高效液相色谱法检测环核苷酸磷酸二酯酶抑制剂活性的方法 |
| WO2025149629A1 (en) | 2024-01-12 | 2025-07-17 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003530398A (ja) * | 2000-04-07 | 2003-10-14 | ノバルティス アクチエンゲゼルシャフト | Ｐｄｅ５阻害剤としての８−キノリンキサンチンおよび８−キノリンキサンチン誘導体 |
| WO2007103554A1 (en) * | 2006-03-08 | 2007-09-13 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| WO2008006372A1 (en) * | 2006-07-10 | 2008-01-17 | H. Lundbeck A/S | (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl- thiomorpholin-4-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline |
| WO2009036766A1 (en) * | 2007-09-19 | 2009-03-26 | H. Lundbeck A/S | Cyanoisoquinoline |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| DE10130167A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
| US20030236276A1 (en) | 2001-08-06 | 2003-12-25 | Ulrich Niewohner | Pyrrolo[2.1-a]isoquinoline derivatives |
| US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
| US20060111368A1 (en) | 2002-06-26 | 2006-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Phosphodiesterase inhibitor |
| DE10230605A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
| DE10230604A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
| JP2009513494A (ja) | 2003-06-30 | 2009-04-02 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｄｅ１０阻害剤としてのピロロジヒドロイソキノリン |
| ATE438398T1 (de) | 2003-06-30 | 2009-08-15 | Nycomed Gmbh | Pyrrolo-dihydroisochinolin-derivate als pde10- inhibitoren |
| CA2534432A1 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| EP1723134A2 (en) | 2004-02-18 | 2006-11-22 | Pfizer Products Incorporated | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
| WO2005120514A1 (en) | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| US20060160814A1 (en) | 2004-09-03 | 2006-07-20 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| WO2006034512A2 (en) | 2004-09-23 | 2006-03-30 | Bayer Pharmaceuticals Corporation | Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes |
| US7576080B2 (en) | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
| US20060183763A1 (en) | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| UA86283C2 (uk) | 2005-01-07 | 2009-04-10 | Пфайзер Продактс Инк. | Гетероароматичні сполуки хіноліну і їх застосування як інгібіторів pde10 |
| EP1838708A2 (en) | 2005-01-12 | 2007-10-03 | Nycomed GmbH | Pyrrolodihydroisoquinolines as antiproliferative agents |
| WO2006089815A1 (en) | 2005-01-12 | 2006-08-31 | Nycomed Gmbh | Novel pyrrolodihydroisoquinolines as pde10 inhibitors |
| US20070093515A1 (en) | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| WO2007085954A2 (en) | 2006-01-27 | 2007-08-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
| WO2007098169A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| MX2008010671A (es) | 2006-02-21 | 2008-10-01 | Amgen Inc | Derivados de cinolina como inhibidores de fosfodiesterasa 10. |
| EP1996587A1 (en) | 2006-02-23 | 2008-12-03 | Pfizer Products Incorporated | Substituted quinazolines as pde10 inhibitors |
| MX2008010953A (es) | 2006-02-28 | 2008-09-08 | Amgen Inc | Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10. |
| US20090099175A1 (en) | 2006-03-01 | 2009-04-16 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| EP2074106B1 (en) | 2006-09-11 | 2013-04-17 | Mylan Laboratories Limited | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
| CN101166128A (zh) | 2006-10-16 | 2008-04-23 | 琥珀技术有限公司 | 一种提供第三方服务的方法及相应的系统 |
| WO2008064342A2 (en) | 2006-11-21 | 2008-05-29 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| US7786139B2 (en) | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| WO2009025839A2 (en) | 2007-08-22 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| US20090054434A1 (en) | 2007-08-23 | 2009-02-26 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| US20090143391A1 (en) | 2007-11-30 | 2009-06-04 | Norbert Hofgen | Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10 |
| US20090143361A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| JP2011505366A (ja) | 2007-11-30 | 2011-02-24 | ワイス・エルエルシー | ホスホエステラーゼ１０の阻害剤としてのアリールおよびヘテロアリール縮合イミダゾ［１，５−ａ］ピラジン |
| WO2009143178A2 (en) | 2008-05-20 | 2009-11-26 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| UA102693C2 (ru) | 2008-06-20 | 2013-08-12 | Х. Луннбек А/С | Производные фенилимидазола как ингибиторы фермента pde10a |
| US8133897B2 (en) | 2008-06-20 | 2012-03-13 | H. Lundbeck A/S | Phenylimidazole derivatives as PDE10A enzyme inhibitors |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| MX2011000175A (es) | 2008-06-25 | 2011-06-27 | Envivo Pharmaceuticals Inc | Compuestos heterociclicos 1,2-di-substituidos. |
| EP2297131A2 (en) | 2008-06-25 | 2011-03-23 | Envivo Pharmaceuticals, Inc. | Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors |
| WO2010006130A2 (en) | 2008-07-09 | 2010-01-14 | Envivo Pharmaceuticals, Inc. | Pde-10 inhibitors |
| CN102143752B (zh) | 2008-08-05 | 2014-12-10 | 奥默罗斯公司 | Pde10抑制剂以及相关组合物和方法 |
| CN102143951A (zh) | 2008-09-04 | 2011-08-03 | 田边三菱制药株式会社 | 三取代嘧啶化合物及其作为pde10抑制剂的用途 |
| CA2741303A1 (en) | 2008-10-28 | 2010-06-03 | Schering Corporation | Substituted pyrazoloquinolines and derivatives thereof |
| WO2010054253A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Triazine derivatives as inhibitors of phosphodiesterases |
| US20100120763A1 (en) | 2008-11-07 | 2010-05-13 | Wyeth | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
| TW201030001A (en) | 2008-11-14 | 2010-08-16 | Amgen Inc | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors |
| EP2373641B1 (en) | 2008-12-04 | 2012-12-19 | F. Hoffmann-La Roche AG | Pyridazinone derivatives |
| JP2012512255A (ja) | 2008-12-17 | 2012-05-31 | アムジエン・インコーポレーテツド | ホスホジエステラーゼ１０阻害剤としてのアミノピリジンおよびカルボキシピリジン化合物 |
| US8354411B2 (en) | 2009-02-05 | 2013-01-15 | Takeda Pharmaceutical Company Limited | 1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound |
| US9187455B2 (en) | 2009-02-23 | 2015-11-17 | Hoffmann-La Roche Inc. | Substituted pyridazines as PDE10A inhibitors |
| US20110305637A1 (en) | 2009-02-24 | 2011-12-15 | Janssen Pharmaceutica N.V. | Radiolabelled pde10 ligands |
| US8685967B2 (en) | 2009-04-07 | 2014-04-01 | Merck Sharp & Dohme Corp. | Substituted triazolopyridines and analogs thereof |
| RU2531274C2 (ru) | 2009-05-07 | 2014-10-20 | Энвиво Фармасьютикалз, Инк. | Феноксиметильные гетероциклические соединения |
| WO2010138430A1 (en) | 2009-05-27 | 2010-12-02 | Merck Sharp & Dohme Corp. | Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors |
| WO2010138585A1 (en) | 2009-05-29 | 2010-12-02 | Merck Sharp & Dohme Corp. | Pyrimidinones as pde10 inhibitors |
| WO2010138833A1 (en) | 2009-05-29 | 2010-12-02 | Wyeth | SUBSTITUTED IMIDAZO[1,5-a]QUINOXALINES AS INHIBITORS OF PHOSPHODIESTERASE 10 |
| JP5718323B2 (ja) | 2009-05-29 | 2015-05-13 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 放射標識されたｐｄｅ１０阻害剤 |
| EP2467382B1 (en) | 2009-08-17 | 2014-06-25 | Merck Sharp & Dohme Corp. | Amino tetrahydro-pyridopyrimidine pde10 inhibitors |
| KR101426624B1 (ko) | 2009-09-24 | 2014-08-05 | 에프. 호프만-라 로슈 아게 | 포스포다이에스터라제 10a 억제제로서 이미다조피리딘 또는 이미다조피리미딘 유도체 |
| US8349830B2 (en) | 2009-10-30 | 2013-01-08 | Merck Sharp & Dohme | Aryl aminopyridine PDE10 inhibitors |
| CA2776240C (en) | 2009-10-30 | 2017-06-13 | Janssen Pharmaceutica Nv | Radiolabelled pde10 ligands |
| JP5641664B2 (ja) | 2009-10-30 | 2014-12-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | イミダゾ［１，２−ｂ］ピリダジン誘導体およびＰＤＥ１０阻害剤としてのそれらの使用 |
| TW201200516A (en) | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
| TWI487705B (zh) | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物 |
| TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| US8470820B2 (en) | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
| PH12012501643A1 (en) | 2010-02-26 | 2017-07-19 | Mitsubishi Tanabe Pharma Corp | Pyrazolopyrimidine compounds and their use as pde 10 inhibitors |
| JP2011201873A (ja) | 2010-03-03 | 2011-10-13 | Mitsubishi Tanabe Pharma Corp | 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用 |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| PT2544679T (pt) | 2010-03-12 | 2019-07-11 | Omeros Corp | Inibidores de pde-10 e composições e métodos relacionados |
| US8410117B2 (en) | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
| WO2011132048A1 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceutical S.A. | Heteroaryl compounds as pde10a inhibitors |
| WO2011132051A2 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Tricycle compounds as phosphodiesterase-10 inhibitors |
| WO2011138657A1 (en) | 2010-05-04 | 2011-11-10 | Glenmark Pharmaceuticals S.A. | Aryl substituted olefinic compounds as pde10a inhibitors |
| JP2013526546A (ja) | 2010-05-13 | 2013-06-24 | アムジエン・インコーポレーテツド | Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物 |
| US8952037B2 (en) | 2010-05-13 | 2015-02-10 | Amgen Inc. | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors |
| PE20130576A1 (es) | 2010-05-13 | 2013-05-19 | Amgen Inc | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10 |
| CN103038229B (zh) | 2010-05-26 | 2016-05-11 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
| US8703768B2 (en) | 2010-06-09 | 2014-04-22 | Hoffmann-La Roche Inc. | Nitrogen containing heteroaryl compounds |
| WO2011163355A1 (en) | 2010-06-24 | 2011-12-29 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors |
| TW201215607A (en) | 2010-07-02 | 2012-04-16 | Lundbeck & Co As H | Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor |
| TW201206935A (en) | 2010-07-16 | 2012-02-16 | Lundbeck & Co As H | Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor |
| CN103476757A (zh) * | 2011-02-18 | 2013-12-25 | 阿勒根公司 | 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物 |
| US9200016B2 (en) * | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
-
2012
- 2012-02-17 CN CN2012800184663A patent/CN103476757A/zh active Pending
- 2012-02-17 BR BR112013021180A patent/BR112013021180A2/pt not_active IP Right Cessation
- 2012-02-17 CA CA2827724A patent/CA2827724A1/en not_active Abandoned
- 2012-02-17 AU AU2012219316A patent/AU2012219316A1/en not_active Abandoned
- 2012-02-17 JP JP2013554657A patent/JP2014510055A/ja active Pending
- 2012-02-17 EP EP12706983.9A patent/EP2675791B1/en active Active
- 2012-02-17 US US13/399,351 patent/US8772316B2/en active Active
- 2012-02-17 WO PCT/US2012/025731 patent/WO2012112946A1/en not_active Ceased
- 2012-02-17 RU RU2013142364/04A patent/RU2013142364A/ru not_active Application Discontinuation
- 2012-02-17 MX MX2013009575A patent/MX2013009575A/es not_active Application Discontinuation
- 2012-02-17 KR KR1020137024525A patent/KR20140009372A/ko not_active Withdrawn
- 2012-02-17 SG SG2013062807A patent/SG192839A1/en unknown
-
2013
- 2013-08-18 IL IL228008A patent/IL228008A0/en unknown
- 2013-08-19 CL CL2013002394A patent/CL2013002394A1/es unknown
- 2013-08-26 ZA ZA2013/06416A patent/ZA201306416B/en unknown
-
2014
- 2014-06-25 US US14/314,930 patent/US9670181B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003530398A (ja) * | 2000-04-07 | 2003-10-14 | ノバルティス アクチエンゲゼルシャフト | Ｐｄｅ５阻害剤としての８−キノリンキサンチンおよび８−キノリンキサンチン誘導体 |
| WO2007103554A1 (en) * | 2006-03-08 | 2007-09-13 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| WO2008006372A1 (en) * | 2006-07-10 | 2008-01-17 | H. Lundbeck A/S | (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl- thiomorpholin-4-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline |
| WO2009036766A1 (en) * | 2007-09-19 | 2009-03-26 | H. Lundbeck A/S | Cyanoisoquinoline |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019509267A (ja) * | 2016-02-12 | 2019-04-04 | アステラス製薬株式会社 | テトラヒドロイソキノリン誘導体 |
| US11479561B2 (en) | 2016-02-12 | 2022-10-25 | Cytokinetics, Incorporated | Tetrahydroisoquinoline derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| US9670181B2 (en) | 2017-06-06 |
| AU2012219316A1 (en) | 2013-10-03 |
| ZA201306416B (en) | 2014-04-30 |
| CL2013002394A1 (es) | 2014-07-04 |
| IL228008A0 (en) | 2013-09-30 |
| BR112013021180A2 (pt) | 2019-09-24 |
| US20140309253A1 (en) | 2014-10-16 |
| RU2013142364A (ru) | 2015-03-27 |
| CN103476757A (zh) | 2013-12-25 |
| EP2675791A1 (en) | 2013-12-25 |
| MX2013009575A (es) | 2014-10-14 |
| KR20140009372A (ko) | 2014-01-22 |
| US8772316B2 (en) | 2014-07-08 |
| CA2827724A1 (en) | 2012-08-23 |
| WO2012112946A1 (en) | 2012-08-23 |
| SG192839A1 (en) | 2013-09-30 |
| US20120214837A1 (en) | 2012-08-23 |
| EP2675791B1 (en) | 2016-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9670181B2 (en) | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | |
| JP5820921B2 (ja) | １，２−二置換複素環式化合物 | |
| US9908885B2 (en) | Bromodomain inhibitors | |
| TWI383982B (zh) | 作為脂激酶抑制劑之咪唑喹啉 | |
| AU2005289644A1 (en) | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases | |
| JP2002501532A (ja) | 新規血管形成阻害薬 | |
| CA2667963A1 (en) | 3-aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators | |
| EP2861590A1 (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| WO2014071044A1 (en) | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) | |
| KR20140014104A (ko) | 치환된 이미다조퀴놀린 유도체 | |
| WO2013053273A1 (zh) | 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用 | |
| KR20140077916A (ko) | 티로신 키나제로서의 6-치환된 3-(퀴놀린-6-일티오)-[1,2,4]트리아졸로[4,3-a]피라딘 | |
| US9902710B2 (en) | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | |
| CN114981256B (zh) | 干扰素基因刺激物sting的单环激动剂 | |
| WO2006077851A1 (ja) | キノロン誘導体又はその塩 | |
| JP2024521900A (ja) | メチオニンアデノシルトランスフェラーゼ２ａ阻害剤 | |
| JP2009501176A (ja) | グリコーゲンシンターゼキナーゼ３阻害薬としてのピリダジン化合物 | |
| JP4858683B2 (ja) | キノロン誘導体又はその塩の製造法 | |
| US9296747B1 (en) | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 | |
| TW201524960A (zh) | 作爲磷酸二酯酶１０（ｐｄｅ１０ａ）抑制劑之經取代６，７－二烷氧基－３－異喹啉衍生物 | |
| JP2005053903A (ja) | キノロン誘導体又はその塩 | |
| TW201943717A (zh) | 類fms酪胺酸激酶抑制劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150217 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150217 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150819 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150820 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151119 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160509 |